Current status of immunotherapy for non-small cell lung cancer

• Автори: Tao Yang (Автор), Yilin Xiong (Автор), Yufei Zeng (Автор), Yan Wang (Автор), Jing Zeng (Автор), Jie Liu (Автор), Shangfu Xu (Автор), Li-Sheng Li (Автор)
• Формат: Книга
• Опубліковано: Frontiers Media S.A., 2022-10-01T00:00:00Z.
• Предмети: article
• Онлайн доступ: Connect to this object online.

Nowadays, lung cancer is still the deadliest oncological disease in the world. Among them, non-small cell lung cancer (NSCLC) accounts for 80%∼85% of all lung cancers, and its 5-year survival rate is less than 15%, making the situation critical. In the past decades, despite some clinical advances in...